Chinanews.com, Shanghai, October 16 (Fan Yubin) At each CIIE, the medical equipment and medicine and health care exhibition area is always full of "new" ideas, and it can always bring together a large number of first, first and first exhibits with great scientific and technological content, becoming one of the hottest exhibition areas.
In 2023, Gilead Sciences, the world's leading biopharmaceutical company, participated in the CIIE for the second time. Gilead Sciences' "suitcase" capacity has increased dramatically from "returning customers" to "returning customers": the booth area has been expanded by 5 times, the innovative product business display area has been expanded by 2 times, and a dedicated R&D pipeline exhibition area has been set up to focus on Gilead Sciences' global R&D pipeline, clinical research and new product launch plans in China.
In 2024, Gilead Sciences will join hands with CIIE for the third time, and the "Suitcase" will be expanded once again, and the 500-square-meter booth will once again showcase its expanding product portfolio and innovations, fully demonstrating its medical innovation capabilities and best practices in working closely with various partners to benefit Chinese patients. The exhibits not only cover the fields of virology, oncology and mycology that Gilead China focuses on, but also include a number of drugs under development for the first time. Jin Fangqian, Global Vice President and General Manager of Gilead Sciences, also expressed his good expectations for the "Appointment to CIIE".
Gilead Science booth at the 6th CIIE. Courtesy of Gilead Sciences
"CIIE babies" appear frequently
Gilead Sciences is headquartered in Foster City, California, United States, and operates in more than 35 countries and territories around the world. In 2017, Gilead Sciences commenced commercial operations in China. Over the past seven years, 11 Gilead Sciences' world-leading drugs have been approved in China, eight of which have been listed in the National Medical Insurance List.
China is one of Gilead Sciences' three most important strategic markets in the world. Gilead Sciences participated in the CIIE twice, witnessed the "spillover effect" brought by the CIIE, and experienced the rapid launch of the exhibited drugs.
In the medical devices and health care exhibition area of the Expo, exhibitors are accustomed to "turning exhibits into commodities" through the Expo, and the innovative drugs and devices used in China are affectionately called "CIIE babies".
Every year after the Expo, a group of "Expo babies" will be born. After Gilead Sciences participated in the CIIE for the first time in 2022, it had its own "CIIE baby", including two new drugs in the field of antifungal and oncology. Among them, the antifungal drug Anbisu ® was approved by the National Medical Products Administration of China only three months after the exhibition, witnessing the "China speed" of accelerating the availability of innovative drugs.
At the 6th CIIE in 2023, the debut of Lenacapavir, Gilead Sciences' "star product" to be launched in China, attracted a lot of attention for its debut.
Jin Fangqian believes that the CIIE has provided an important boost to promote the overall process of innovative drug listing, and has become an "accelerator" to promote drug innovation and development.
Visitors visit the Gilead Science booth. Courtesy of Gilead Sciences
Expanding the "Ecosystem" of Medical Cooperation
Exhibiting at the CIIE twice, CIIE has become an "accelerator" to promote the development of Gilead Sciences in China. With the help of this large open platform, Gilead Sciences continues to deepen its cooperation and exchanges with all parties.
At the 5th CIIE, Gilead Sciences and the China Foundation for the Prevention of STDs and AIDS launched a three-year collaborative project on the follow-up management of hepatitis C cases to support the national effort to eliminate the public health hazard of hepatitis C.
At the 6th CIIE, Gilead Sciences and the China Association for the Prevention and Treatment of STDs and AIDS signed a cooperation agreement on the HIV Rapid Start Program, advocating early access to standardized treatment for people living with HIV, and partnering with the Beijing Heathco Clinical Oncology Research Foundation to establish the "Heath-Gilead Oncology Research Fund" to promote the transformation of scientific research in the field of oncology.
These projects are a vivid microcosm of Gilead's deepening partnership with China's healthcare ecosystem through the Expo. Jin Fangqian said that he looks forward to using the platform of the CIIE to further expand the "circle of friends" in the medical ecosystem.
Gilead Sciences' drugs on display at the CIIE. Courtesy of Gilead Sciences
Increase R&D investment in China
As an important platform for foreign-funded enterprises to share China's development opportunities, CIIE has become an important channel for the world's leading pharmaceutical companies to link with the Chinese market. Through participating in the CIIE, Gilead Sciences experienced the platform effect of "turning exhibits into commodities", deeply realized China's determination to share development opportunities with other countries around the world, and further strengthened its confidence in taking root in the Chinese market and deepening local pharmaceutical innovation.
Nowadays, the Chinese market as "the world's market, the shared market, everyone's market" has become an international consensus. Since 2022, Gilead China has invested heavily in local R&D and initiated a number of clinical research projects, including Phase III clinical development in parallel with the world, covering multiple diseases in the fields of cancer and virology, aiming to promote the "synchronous" launch of more innovative therapies in China to benefit more patients in need.
Gilead Sciences is committed to pushing the boundaries of the impossible. Jin Fangqian said that in the future, Gilead Sciences will continue to be patient-centric, explore innovative cooperation with all parties, strengthen multi-channel construction, continuously improve the accessibility of marketed drugs, and continue to promote the construction of local R&D capabilities, so that more innovative drugs can benefit Chinese patients as soon as possible. (ENDS)
Editor: Wang Danqin